Understanding Spinal Muscular Atrophy: A Chief Scientific Officer's Perspective
PharmaTalkRadio14 Apr 2020

Understanding Spinal Muscular Atrophy: A Chief Scientific Officer's Perspective

In the second episode of a three-part series dedicated to highlighting rare disease, Conference Forum reporter Danny McCarthy sits down with C Frank Bennett, PhD, of Ionis Pharmaceuticals, to discuss Spinal Muscular Atrophy. Dr Bennett is Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, and one of the founding members of the company. He is responsible for continuing to advance antisense technology and expanding Ionis drug discovery platform. Dr. Bennet is a co-recipient of the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen). Spinal muscular atrophy is a genetic, degenerative neuromuscular disorder characterized by weakness and wasting in muscles used for movement. It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. Dr Bennett includes two sources of information about Ionis and SMA: Ionispharma.com and Spinraza.com.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(461)

Populært innen Vitenskap

fastlegen
tingenes-tilstand
rekommandert
jss
sinnsyn
liberal-halvtime
forskningno
tomprat-med-gunnar-tjomlid
fjellsportpodden
rss-overskuddsliv
villmarksliv
dekodet-2
rss-paradigmepodden
rss-inn-til-kjernen-med-sunniva-rose
rss-zahid-ali-hjelper-deg
kvinnehelsepodden
rss-rekommandert
hva-er-greia-med
nevropodden
aldring-og-helse-podden